EP0914123A4 - THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS - Google Patents

THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS

Info

Publication number
EP0914123A4
EP0914123A4 EP97927902A EP97927902A EP0914123A4 EP 0914123 A4 EP0914123 A4 EP 0914123A4 EP 97927902 A EP97927902 A EP 97927902A EP 97927902 A EP97927902 A EP 97927902A EP 0914123 A4 EP0914123 A4 EP 0914123A4
Authority
EP
European Patent Office
Prior art keywords
thalidomide
prodrugs
modulators
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97927902A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0914123A1 (en
Inventor
Robert E Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prototek Inc
Original Assignee
Prototek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prototek Inc filed Critical Prototek Inc
Publication of EP0914123A1 publication Critical patent/EP0914123A1/en
Publication of EP0914123A4 publication Critical patent/EP0914123A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97927902A 1996-05-29 1997-05-29 THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS Withdrawn EP0914123A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1855896P 1996-05-29 1996-05-29
US18558P 1996-05-29
PCT/US1997/009421 WO1997045117A1 (en) 1996-05-29 1997-05-29 Prodrugs of thalidomide and methods for using same as modulators of t-cell function

Publications (2)

Publication Number Publication Date
EP0914123A1 EP0914123A1 (en) 1999-05-12
EP0914123A4 true EP0914123A4 (en) 2000-10-11

Family

ID=21788567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97927902A Withdrawn EP0914123A4 (en) 1996-05-29 1997-05-29 THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS

Country Status (5)

Country Link
EP (1) EP0914123A4 (cs)
AU (1) AU3224997A (cs)
CA (1) CA2256669A1 (cs)
CZ (1) CZ389398A3 (cs)
WO (1) WO1997045117A1 (cs)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
CA2370245A1 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
DE19926233C1 (de) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
ES2525041T3 (es) 2000-03-31 2014-12-16 Royalty Pharma Collection Trust Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
PT1480961E (pt) 2002-02-28 2007-02-28 Prosidion Ltd Inibidores de dpiv à base de glutaminilo
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
KR20100038477A (ko) 2003-05-05 2010-04-14 프로비오드룩 아게 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
BRPI0414497A (pt) 2003-09-17 2006-11-14 Us Gov Health & Human Serv análogos de talidomida
CN1867324A (zh) 2003-10-15 2006-11-22 前体生物药物股份公司 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018496A1 (de) * 1991-04-17 1992-10-29 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
WO1997037988A1 (de) * 1996-04-09 1997-10-16 Grünenthal GmbH Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229997A (ja) * 1985-04-08 1987-02-07 Sankyo Co Ltd Ｃ末端にプロリンアミドを有するペプチドの製法
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018496A1 (de) * 1991-04-17 1992-10-29 Grünenthal GmbH Neue thalidomidderivate, ein verfahren zu deren herstellung sowie die verwendung derselben in arzneimitteln
WO1997037988A1 (de) * 1996-04-09 1997-10-16 Grünenthal GmbH Acylierte n-hydroxymethyl thalidomid-prodrugs mit immunomodulatorischer wirkung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'AMATO R J ET AL: "Thalidomide is an inhibitor of angiogenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1994 APR 26) 91 (9) 4082-5., XP002917515 *
GUCKIAN, M. (1) ET AL: "Thalidomide analog 3052 reduces NK activity and PHA-induced proliferation in vitro.", IMMUNOLOGY, (1996) VOL. 89, NO. SUPPL. 1, PP. 34. MEETING INFO.: JOINT CONGRESS OF THE BRITISH SOCIETY FOR IMMUNOLOGY AND THE BIOCHEMICAL SOCIETY HARROGATE, ENGLAND, UK DECEMBER 10-13, 1996, XP000917548 *
See also references of WO9745117A1 *

Also Published As

Publication number Publication date
EP0914123A1 (en) 1999-05-12
WO1997045117A1 (en) 1997-12-04
CZ389398A3 (cs) 1999-07-14
CA2256669A1 (en) 1997-12-04
AU3224997A (en) 1998-01-05

Similar Documents

Publication Publication Date Title
EP0914123A4 (en) THALIDOMIDE PRODUCTS AND METHODS OF USING SAID PRODUCTS AS T CELL MODIFIERS
GB2344559B (en) Compaction methods and apparatus
EP0894885B8 (en) Method and apparatus for molding fiber mixture
HUP9902770A3 (en) Modulators of tissue regeneration
HUP9904009A3 (en) Method and novel compounds for use therein
IL129389A0 (en) Compounds and methods for diagnsosis of tuberculosis
GB2314741B (en) Encryption apparatus
GB2312600B (en) Audio apparatus
GB9712752D0 (en) Disc clamping apparatus
AU7758698A (en) Method and apparatus for distributing long fibers
AU8287798A (en) Adsorption apparatus and methods
AU2500797A (en) Methods of modulating t-cell activation
GB2315379B (en) Non-linear filter apparatus
AU3423397A (en) Therapeutic methods and compositions for use therein
GB9625667D0 (en) Modulators
GB9823314D0 (en) Methods and apparatus
GB2332771B (en) Audio apparatus
HU1001U (en) Set of device
GB9904847D0 (en) Compaction methods and apparatus
AU2002100822A4 (en) Apparatus and methods for assessment of neuromusclar function
GB9607110D0 (en) Benzothiopenes formulations containing same and methods
AUPN768596A0 (en) Holding apparatus
GB9703026D0 (en) Audio tester apparatus
GB9604351D0 (en) Audio tester apparatus
GB9606360D0 (en) Analytic instrument

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/445 A

A4 Supplementary search report drawn up and despatched

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20001114